Video Experimental Relacionado
Updated: Sep 10, 2025
07:29
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
9.4K
Cerrando la brecha entre las enfermedades cardiovasculares y el COVID-19: la hipótesis de LDL oxidado
1Department of Biology, Faculty of Arts and Sciences, University of Balamand, El-Koura, Lebanon.
Frontiers in medicine
|August 22, 2025
Resumen
Dirigirse a la dislipidemia inflamatoria puede mejorar los resultados para los pacientes con COVID-19. Este enfoque aborda la disfunción endotelial y las alteraciones del metabolismo lipídico relacionadas con enfermedades graves y complicaciones cardiovasculares.
Área de la Ciencia:
- Medicina cardiovascular
- Virología
- La bioquímica
Sus antecedentes:
- El coronavirus 2 del síndrome respiratorio agudo severo (SARS-CoV-2) causa COVID-19, lo que afecta la salud cardiovascular.
- La disfunción endotelial (DE), vinculada a las enfermedades cardiovasculares (ECV), juega un papel clave en la patogénesis del COVID-19.
- La disfunción eréctil asociada con COVID-19 puede deberse a un metabolismo lipídico desregulado, con lipoproteínas de baja y alta densidad (HDL) correlacionadas con la gravedad de la enfermedad.
Objetivo del estudio:
- Para formular la hipótesis de que el tratamiento de la dislipidemia inflamatoria puede beneficiar a los pacientes con COVID-19.
- Para explorar el vínculo entre el metabolismo lipídico, la disfunción endotelial y las complicaciones del COVID-19.
- Para investigar el papel de la lipoproteína de baja densidad oxidada por mieloperoxidasa (Mox-LDL) en la patogénesis de COVID-19.
Principales métodos:
- Revisión de la evidencia emergente sobre el COVID-19, las enfermedades cardiovasculares y el metabolismo lipídico.
- Análisis del papel de la enzima convertidora de angiotensina 2 (ACE 2) en la entrada viral y los síntomas cardiovasculares.
- Examen de la actividad anti-fibrinolítica del Mox-LDL en las células endoteliales.
Principales resultados:
- La expresión de ACE 2 en el endotelio puede explicar los síntomas cardiovasculares en COVID-19.
- La disminución de la capacidad antioxidante de HDL puede conducir a la generación de LDL oxidado (oxLDL) y Mox-LDL.
- El Mox-LDL exhibe actividad anti-fibrinolítica, aumentando potencialmente los riesgos de coagulación intravascular diseminada y accidentes cerebrovasculares isquémicos.
Conclusiones:
- La dislipidemia inflamatoria es un factor significativo en la patogénesis del COVID-19.
- Dirigirse a la dislipidemia inflamatoria presenta una estrategia terapéutica prometedora para el COVID-19.
- La investigación adicional sobre la modulación del metabolismo lipídico podría mejorar los resultados clínicos para los pacientes con COVID-19.
Palabras clave:
El COVID-19HDL y sus derivadosEl colesterol bajola aterosclerosisEnfermedad cardiovascularDislipidemiaDisfunción endotelialLDL oxidadoMás Videos Relacionados
Videos de Conceptos Relacionados
01:30Coronary Artery Disease I: Introduction
55
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
55
01:26Coronary Artery Disease II: Pathophysiology
34
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
34
01:27Psychoneuroimmunology: Cardiovascular Disease
78
Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
A key area of focus in PNI is the relationship between stress and coronary...
78
01:26Coronary Artery Disease IV: Preventive Measures
32
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
32
01:30Atherosclerosis I: Introduction
77
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
77
01:26Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33